193 related articles for article (PubMed ID: 31409771)
1. Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis.
Kodrič K; Zupan J; Kranjc T; Komadina R; Mlakar V; Marc J; Lovšin N
Exp Mol Med; 2019 Aug; 51(8):1-16. PubMed ID: 31409771
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12.
Lian WS; Ko JY; Chen YS; Ke HJ; Hsieh CK; Kuo CW; Wang SY; Huang BW; Tseng JG; Wang FS
Cell Death Dis; 2019 Sep; 10(10):705. PubMed ID: 31543513
[TBL] [Abstract][Full Text] [Related]
3. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.
Rinotas V; Niti A; Dacquin R; Bonnet N; Stolina M; Han CY; Kostenuik P; Jurdic P; Ferrari S; Douni E
J Bone Miner Res; 2014; 29(5):1158-69. PubMed ID: 24127173
[TBL] [Abstract][Full Text] [Related]
4. Vps35 loss promotes hyperresorptive osteoclastogenesis and osteoporosis via sustained RANKL signaling.
Xia WF; Tang FL; Xiong L; Xiong S; Jung JU; Lee DH; Li XS; Feng X; Mei L; Xiong WC
J Cell Biol; 2013 Mar; 200(6):821-37. PubMed ID: 23509071
[TBL] [Abstract][Full Text] [Related]
5. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.
Zupan J; Komadina R; Marc J
J Biomed Sci; 2012 Mar; 19(1):28. PubMed ID: 22380539
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
7. Influence of Palmatine on Bone Metabolism in Ovariectomized Mice and Cytokine Secretion of Osteoblasts.
Ishikawa S; Ogawa Y; Tamaki M; Takashima M; Tajika Y; Moue T; Zhang M; Kusayanagi H; Sunagawa M; Hisamitsu T
In Vivo; 2015; 29(6):671-7. PubMed ID: 26546523
[TBL] [Abstract][Full Text] [Related]
8. Opg/Rankl mRNA dynamic expression in the bone tissue of ovariectomized rats with osteoporosis.
Li CW; Liang B; Shi XL; Wang H
Genet Mol Res; 2015 Aug; 14(3):9215-24. PubMed ID: 26345854
[TBL] [Abstract][Full Text] [Related]
9. Role of DNA methylation in the regulation of the RANKL-OPG system in human bone.
Delgado-Calle J; Sañudo C; Fernández AF; García-Renedo R; Fraga MF; Riancho JA
Epigenetics; 2012 Jan; 7(1):83-91. PubMed ID: 22207352
[TBL] [Abstract][Full Text] [Related]
10. Influence of DNA methylation on the expression of OPG/RANKL in primary osteoporosis.
Wang P; Cao Y; Zhan D; Wang D; Wang B; Liu Y; Li G; He W; Wang H; Xu L
Int J Med Sci; 2018; 15(13):1480-1485. PubMed ID: 30443169
[No Abstract] [Full Text] [Related]
11. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid Receptor Regulates
Lovšin N; Marc J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494362
[TBL] [Abstract][Full Text] [Related]
14. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
15. Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.
Jurado S; Garcia-Giralt N; Díez-Pérez A; Esbrit P; Yoskovitz G; Agueda L; Urreizti R; Pérez-Edo L; Saló G; Mellibovsky L; Balcells S; Grinberg D; Nogués X
J Cell Biochem; 2010 May; 110(2):304-10. PubMed ID: 20225238
[TBL] [Abstract][Full Text] [Related]
16. Association of
Abdi S; Binbaz RA; Mohammed AK; Ansari MGA; Wani K; Amer OE; Alnaami AM; Aljohani N; Al-Daghri NM
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572979
[TBL] [Abstract][Full Text] [Related]
17. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.
Yao Z; Lei W; Duan R; Li Y; Luo L; Boyce BF
J Biol Chem; 2017 Jun; 292(24):10169-10179. PubMed ID: 28438834
[TBL] [Abstract][Full Text] [Related]
18. Switching on sex: transcriptional regulation of the testis-determining gene Sry.
Larney C; Bailey TL; Koopman P
Development; 2014 Jun; 141(11):2195-205. PubMed ID: 24866114
[TBL] [Abstract][Full Text] [Related]
19. Multiple Functional Variants at 13q14 Risk Locus for Osteoporosis Regulate RANKL Expression Through Long-Range Super-Enhancer.
Zhu DL; Chen XF; Hu WX; Dong SS; Lu BJ; Rong Y; Chen YX; Chen H; Thynn HN; Wang NN; Guo Y; Yang TL
J Bone Miner Res; 2018 Jul; 33(7):1335-1346. PubMed ID: 29528523
[TBL] [Abstract][Full Text] [Related]
20. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
